【佳學(xué)基因檢測】生物標(biāo)志物鑒定的基因組方法及其近期應(yīng)用

基因檢測有必要做嗎—解答

研討《腫瘤靶向藥物的敏感性及有效性》《Cancer Biomark》在?2006;2(3-4):103-33發(fā)表了一篇題目為《生物標(biāo)志物鑒定的基因組方法及其近期應(yīng)用》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Yudong D He?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞：

0

腫瘤靶向治療基因檢測臨床應(yīng)用結(jié)果

本文討論了使用賊先進(jìn)的基因組方法在生物標(biāo)志物識別和驗(yàn)證中分析方法和應(yīng)用的賊新發(fā)展中的選定活動、問題和挑戰(zhàn)。通過基因組學(xué)、蛋白質(zhì)組學(xué)和代謝組學(xué)進(jìn)行分子分析為研究疾病狀態(tài)和生物系統(tǒng)打開了新的窗口。它還為臨床研究以及藥物發(fā)現(xiàn)和開發(fā)中的新應(yīng)用提供了令人興奮的機(jī)會。在過去的幾年里，我們見證了巨大的進(jìn)步，特別是 mRNA 或轉(zhuǎn)錄組學(xué)的基因表達(dá)譜。在簡要回顧了使用微陣列進(jìn)行基因表達(dá)譜分析的技術(shù)進(jìn)步后，我主要討論了基因組方法在兩種主要類型的應(yīng)用中用于生物標(biāo)志物識別和驗(yàn)證的賊新進(jìn)展。先進(jìn)種類型涉及基于腫瘤基因表達(dá)譜的癌癥診斷和預(yù)后示例，而第二種類型涉及藥物發(fā)現(xiàn)和開發(fā)中的生物標(biāo)志物應(yīng)用。重點(diǎn)將放在近年來開發(fā)的分析方法和算法上，這些方法和算法通過利用源自微陣列的全基因組表達(dá)譜來促進(jìn)生物標(biāo)志物的發(fā)現(xiàn)和應(yīng)用。還討論了與生物標(biāo)志物發(fā)現(xiàn)和應(yīng)用相關(guān)的實(shí)驗(yàn)設(shè)計(jì)、數(shù)據(jù)處理、錯(cuò)誤建模、質(zhì)量控制、性能評估的品質(zhì)因數(shù)以及薈萃分析中的技術(shù)問題。在結(jié)束語之前介紹了基于腫瘤表達(dá)模式的乳腺癌患者疾病預(yù)后預(yù)后的案例研究。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述：

This paper discusses selected activities, issues, and challenges in recent development of analytical methods and applications in biomarker identification and validation using state-of-the-art genomic approaches. Molecular profiling via genomics, proteomics, and metabonomics has opened new windows to study disease states and biological systems. It has also provided exciting opportunities for novel applications in clinical research as well as in drug discovery and development. In the past several years, we have witnessed enormous progress resulting particularly from gene expression profiling of mRNA or transcriptomics. After a brief review on technology advances in gene expression profiling using microarrays, I mainly discuss recent developments of the genomic approaches to biomarker identification and validation in two major types of applications. The first type involves examples in cancer diagnostics and prognostics based on tumor gene expression profiling, whereas the second type involves biomarker applications in drug discovery and development. The focus will be on analytical methods and algorithms that have been developed in recent years facilitating biomarker discovery and application by leveraging genome-wide expression profiles derived from microarrays. Technical issues in experimental design, data processing, error modeling, quality control, figures of merit for performance evaluation, and meta-analysis related to biomarker discovery and application are also discussed. A case study of disease outcome prognosis for breast cancer patients based on tumor expression pattern is presented before closing remarks.